X
RYTM icon

Xponance’s Rhythm Pharmaceuticals RYTM Stock Holding History

Xponance’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$607K Buy
5,465
+475
+10% +$42.9K ﹤0.01% 1008
2026
Q1 		$434K Buy
4,990
+721
+17% +$70.1K ﹤0.01% 1067
2025
Q4 		$457K Buy
4,269
+107
+3% +$11.3K ﹤0.01% 991
2025
Q3 		$420K Sell
4,162
-110
-3% -$10.2K ﹤0.01% 1028
2025
Q2 		$270K Sell
4,272
-93
-2% -$5.69K ﹤0.01% 1181
2025
Q1 		$231K Buy
4,365
+197
+5% +$10.9K ﹤0.01% 1213
2024
Q4 		$233K Buy
+4,168
New +$230K ﹤0.01% 1234

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Xponance's RYTM Position: Q2 2026 in Review

Xponance increased its Rhythm Pharmaceuticals (RYTM) stake by 9.5% in Q2 2026, buying an estimated $42.9K and bringing the position to 5,465 shares worth $607K. The position accounts for ﹤0.01% of the portfolio, ranked #1008.

Xponance first reported a position in RYTM in Q4 2024 and has held it in 7 quarters since. 303 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Xponance held 5,465 shares of Rhythm Pharmaceuticals worth $607K as of Q2 2026.
  • Xponance bought 475 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $42.9K.
  • Rhythm Pharmaceuticals made up ﹤0.01% of Xponance's portfolio in Q2 2026, its #1008 holding.
  • Xponance first reported a position in Rhythm Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • 303 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.